Avastin Receives Positive Opinion In Europe For First-line Treatment Of Patients With Advanced Kidney Cancer

Roche announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for Avastin (bevacizumab) for the first-line treatment of patients with the most common form of advanced kidney cancer, renal cell carcinoma (RCC). [click link for full article]

More: continued here

Filed under: Cancer on November 18th, 2007